{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:15:00Z","timestamp":1783746900961,"version":"3.55.0"},"reference-count":33,"publisher":"Japanese Society of Toxicologic Pathology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Toxicol Pathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1293\/tox.2025-0083","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:08:45Z","timestamp":1772662125000},"page":"93-101","source":"Crossref","is-referenced-by-count":0,"title":["Multinucleation and cytotoxicity induced by multikinase inhibition in highly proliferative cells"],"prefix":"10.1293","volume":"39","author":[{"given":"Emi","family":"Tomikawa","sequence":"first","affiliation":[{"name":"Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Hattori","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamasa","family":"Arai","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Bio Research, Kamakura Techno-Science, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-0036, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Goto","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Yagi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Medical Development Department, Toray Industries, Inc., 2-1-1 Nihonbashi-muromachi, Chuo-ku, Tokyo 103-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"121","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hattori H, Osumi K, Tanaka M, Arai T, Nishimura K, Yamamoto N, Sakamoto K, Goto Y, and Sugawara Y. Discovery of 5-phenyl-3-ureidothiophene-2-carboxamides as protective agents for ALS patient iPSC-derived motor neurons. Bioorg Med Chem Lett. 113: 129935. 2024.","DOI":"10.1016\/j.bmcl.2024.129935"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Watts ME, Giadone RM, Ordureau A, Holton KM, Harper JW, and Rubin LL. Analyzing the ER stress response in ALS patient derived motor neurons identifies druggable neuroprotective targets. Front Cell Neurosci. 17: 1327361. 2024.","DOI":"10.3389\/fncel.2023.1327361"},{"key":"3","unstructured":"3. Japan Patent Office. Japanese Patent Application Publication JP-2024-108241 A. 2024, from website: https:\/\/www.j-platpat.inpit.go.jp\/."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Puls LN, Eadens M, and Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist. 16: 566\u2013578. 2011.","DOI":"10.1634\/theoncologist.2010-0408"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, and Hajduch M. Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 30: 2411\u20132432. 2012.","DOI":"10.1007\/s10637-012-9798-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shi J, and Wei L. Rho kinases in embryonic development and stem cell research. Arch Immunol Ther Exp (Warsz). 70: 4. 2022.","DOI":"10.1007\/s00005-022-00642-z"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Zhang J, Yang PL, and Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 9: 28\u201339. 2009.","DOI":"10.1038\/nrc2559"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jovanovic D, Yan S, and Baumgartner M. The molecular basis of the dichotomous functionality of MAP4K4 in proliferation and cell motility control in cancer. Front Oncol. 12: 1059513. 2022.","DOI":"10.3389\/fonc.2022.1059513"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ndubaku CO, Crawford TD, Chen H, Boggs JW, Drobnick J, Harris SF, Jesudason R, McNamara E, Nonomiya J, Sambrone A, Schmidt S, Smyczek T, Vitorino P, Wang L, Wu P, Yeung S, Chen J, Chen K, Ding CZ, Wang T, Xu Z, Gould SE, Murray LJ, and Ye W. Structure-based design of GNE-495, a potent and selective MAP4K4 inhibitor with efficacy in retinal angiogenesis. ACS Med Chem Lett. 6: 913\u2013918. 2015.","DOI":"10.1021\/acsmedchemlett.5b00174"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bos PH, Lowry ER, Costa J, Thams S, Garcia-Diaz A, Zask A, Wichterle H, and Stockwell BR. Development of MAP4 kinase inhibitors as motor-neuron-protecting agents. Cell Chem Biol. 26: 1703\u20131715.e37. 2019.","DOI":"10.1016\/j.chembiol.2019.10.005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Dow RL, Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Cortes C, El-Kattan AF, Ford K, Freeman GB, Guimar\u00e3es CRW, Liu S, Niosi M, Skoura A, and Tess D. 2-Aminopyridine-based mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) inhibitors: assessment of mechanism-based safety. J Med Chem. 61: 3114\u20133125. 2018.","DOI":"10.1021\/acs.jmedchem.8b00152"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gonz\u00e1lez-Montero J, Rojas CI, and Burotto M. MAP4K4 and cancer: ready for the main stage? Front Oncol. 13: 1162835. 2023.","DOI":"10.3389\/fonc.2023.1162835"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hayashi M, Sofuni T, and Ishidate M Jr. An application of Acridine Orange fluorescent staining to the micronucleus test. Mutat Res. 120: 241\u2013247. 1983.","DOI":"10.1016\/0165-7992(83)90096-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wright JH, Wang X, Manning G, LaMere BJ, Le P, Zhu S, Khatry D, Flanagan PM, Buckley SD, Whyte DB, Howlett AR, Bischoff JR, Lipson KE, and Jallal B. The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol. 23: 2068\u20132082. 2003.","DOI":"10.1128\/MCB.23.6.2068-2082.2003"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lacroix B, and Maddox AS. Cytokinesis, ploidy and aneuploidy. J Pathol. 226: 338\u2013351. 2012.","DOI":"10.1002\/path.3013"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Chen EH, and Olson EN. Unveiling the mechanisms of cell-cell fusion. Science. 308: 369\u2013373. 2005.","DOI":"10.1126\/science.1104799"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yokoyama T, Goto H, Izawa I, Mizutani H, and Inagaki M. Aurora-B and Rho-kinase\/ROCK, the two cleavage furrow kinases, independently regulate the progression of cytokinesis: possible existence of a novel cleavage furrow kinase phosphorylates ezrin\/radixin\/moesin (ERM). Genes Cells. 10: 127\u2013137. 2005.","DOI":"10.1111\/j.1365-2443.2005.00824.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yoshida K, Ono M, Bito H, Mikami T, and Sawada H. Plasmodium induced by SU6656, an Src family kinase inhibitor, is accompanied by a contractile ring defect. Cell Biochem Funct. 30: 33\u201340. 2012.","DOI":"10.1002\/cbf.1814"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Asteriti IA, Di Cesare E, De Mattia F, Hilsenstein V, Neumann B, Cundari E, Lavia P, and Guarguaglini G. The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy. Oncotarget. 5: 6229\u20136242. 2014.","DOI":"10.18632\/oncotarget.2190"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hyodo T, Ito S, Hasegawa H, Asano E, Maeda M, Urano T, Takahashi M, Hamaguchi M, and Senga T. Misshapen-like kinase 1 (MINK1) is a novel component of striatin-interacting phosphatase and kinase (STRIPAK) and is required for the completion of cytokinesis. J Biol Chem. 287: 25019\u201325029. 2012.","DOI":"10.1074\/jbc.M112.372342"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Xia J, Zhao H, Edmondson JL, Koss B, and Zhan F. Role of NEK2 in tumorigenesis and tumor progression. Trends Mol Med. 31: 79\u201393. 2025.","DOI":"10.1016\/j.molmed.2024.07.013"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Fagundes R, and Teixeira LK. Cyclin E\/CDK2: DNA replication, replication stress and genomic instability. Front Cell Dev Biol. 9: 774845. 2021.","DOI":"10.3389\/fcell.2021.774845"},{"key":"23","unstructured":"23. Tanaka T, Yoshimi N, and Nishikawa A. Shouchou daichou [Small and large intestine]. In: Shin-dokusei Byouri Soshikigaku [New Toxicologic Histopathology] 1st ed. (Japanese Society of Toxicologic Pathology (JSTP), ed.), Nishimura, Tokyo, 188\u2013215. 2017 (in Japanese)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Mross K, Richly H, Frost A, Scharr D, Nokay B, Graeser R, Lee C, Hilbert J, Goeldner RG, Fietz O, and Scheulen ME. A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 78: 405\u2013417. 2016.","DOI":"10.1007\/s00280-016-3095-6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Collinge M, Ball DJ, Bowman CJ, Nilson AL, Radi ZA, and Vogel WM. Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats\u2014comparison of juvenile and adult responses. Regul Toxicol Pharmacol. 94: 306\u2013322. 2018.","DOI":"10.1016\/j.yrtph.2018.02.006"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Alu A, Lei H, Han X, Wei Y, and Wei X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol. 15: 138. 2022.","DOI":"10.1186\/s13045-022-01353-w"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Gim\u00e9nez N, Schulz R, Higashi M, Aymerich M, Villamor N, Delgado J, Juan M, L\u00f3pez-Guerra M, Campo E, Rosich L, Seiffert M, and Colomer D. Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. Leukemia. 34: 100\u2013114. 2020.","DOI":"10.1038\/s41375-019-0507-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Bekier ME, Fischbach R, Lee J, and Taylor WR. Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. Mol Cancer Ther. 8: 1646\u20131654. 2009.","DOI":"10.1158\/1535-7163.MCT-08-1084"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, Foster J, Hall PA, Low S, Taylor P, Ellston R, Polanska UM, Wilson J, Howes C, Smith A, Goodwin RJ, Swales JG, Strittmatter N, Tak\u00e1ts Z, Nilsson A, Andren P, Trueman D, Walker M, Reimer CL, Troiano G, Parsons D, De Witt D, Ashford M, Hrkach J, Zale S, Jewsbury PJ, and Barry ST. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 8: 325ra17. 2016.","DOI":"10.1126\/scitranslmed.aad2355"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Drumond AL, Weng CC, Wang G, Chiarini-Garcia H, Eras-Garcia L, and Meistrich ML. Effects of multiple doses of cyclophosphamide on mouse testes: accessing the germ cells lost, and the functional damage of stem cells. Reprod Toxicol. 32: 395\u2013406. 2011.","DOI":"10.1016\/j.reprotox.2011.09.010"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Liu M, Hales BF, and Robaire B. Effects of four chemotherapeutic agents, bleomycin, etoposide, cisplatin, and cyclophosphamide, on DNA damage and telomeres in a mouse spermatogonial cell line. Biol Reprod. 90: 72. 2014.","DOI":"10.1095\/biolreprod.114.117754"},{"key":"32","unstructured":"32. Chatani F, and Kandori H. Yusei-seisyokuki [Male reproductive system]. In: Shin-dokusei Byouri Soshikigaku [New Toxicologic Histopathology] 1st ed. (Japanese Society of Toxicologic Pathology (JSTP), eds.), Nishimura, Tokyo, 347\u2013378. 2017 (in Japanese)."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Sazonova EV, Petrichuk SV, Kopeina GS, and Zhivotovsky B. A link between mitotic defects and mitotic catastrophe: detection and cell fate. Biol Direct. 16: 25. 2021.","DOI":"10.1186\/s13062-021-00313-7"}],"container-title":["Journal of Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tox\/39\/3\/39_2025-0083\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:09:08Z","timestamp":1783746548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tox\/39\/3\/39_2025-0083\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1293\/tox.2025-0083","relation":{},"ISSN":["0914-9198","1881-915X"],"issn-type":[{"value":"0914-9198","type":"print"},{"value":"1881-915X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2025-0083"}}